Pulmatrix (PULM) Operating Income (2013 - 2026)
Pulmatrix (PULM) posted Operating Income of -$1.3 million for Q1 2026, down 42.29% sequentially from -$908000.0 in Q4 2025, and up 30.05% YoY from -$993473.8 in Q1 2025.
Pulmatrix (PULM) Operating Income (2013 - 2026) Analysis & Trends
Pulmatrix has reported Operating Income for 14 years, with the latest figure at -$1.3 million in Q1 2026.
- Quarterly Operating Income rose 30.05% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.6 million (up 62.66% YoY) and the FY2025 annual result came in at -$5.2 million, up 47.06% from the prior year.
- Operating Income retreated to -$1.3 million in Q1 2026 per PULM's latest filing, from -$908000.0 in the prior quarter.
- Over five years, Operating Income peaked at $747000.0 in Q1 2024 and troughed at -$5.9 million in Q2 2024.
- A 5-year average of -$2.9 million and a median of -$2.7 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2025: Operating Income jumped 116.29% in 2024, then plunged 347.26% in 2025.
- Over 5 years, Operating Income stood at -$4.3 million in 2022, then soared by 48.55% to -$2.2 million in 2023, then gained by 12.27% to -$2.0 million in 2024, then jumped by 53.48% to -$908000.0 in 2025, then tumbled by 42.29% to -$1.3 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$1.3 million, -$908000.0, and -$866000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Pulmatrix | 5.66 Mn | 5.66 Mn | - | -1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.05 Mn |
| Mar 31, 2026 | -1.29 Mn |
| Dec 31, 2025 | -908,000.00 |
| Sep 30, 2025 | -866,000.00 |
| Jun 30, 2025 | -1.55 Mn |
| Mar 31, 2025 | -1.85 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Sep 30, 2024 | -2.66 Mn |
| Jun 30, 2024 | -5.90 Mn |
| Mar 31, 2024 | 747,000.00 |
| Dec 31, 2023 | -2.23 Mn |
| Sep 30, 2023 | -3.94 Mn |
| Jun 30, 2023 | -3.99 Mn |
| Mar 31, 2023 | -4.59 Mn |
| Dec 31, 2022 | -4.33 Mn |
| Sep 30, 2022 | -5.10 Mn |
| Jun 30, 2022 | -4.56 Mn |
| Mar 31, 2022 | -4.96 Mn |
| Dec 31, 2021 | -4.04 Mn |
| Sep 30, 2021 | -8.19 Mn |